- Trials with a EudraCT protocol (88)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
88 result(s) found for: Homozygote.
Displaying page 1 of 5.
EudraCT Number: 2020-005111-51 | Sponsor Protocol Number: 20170199 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023742-79 | Sponsor Protocol Number: AEG 733-012 | Start Date*: 2011-03-25 | |||||||||||
Sponsor Name:AEGERION PHARMACEUTICALS | |||||||||||||
Full Title: A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000411-32 | Sponsor Protocol Number: R1500-CL-1331 | Start Date*: 2016-07-15 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002755-38 | Sponsor Protocol Number: CKJX839C12302 | Start Date*: 2020-12-30 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Two part (double-blind) inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2] randomized multicentre study to evaluate safety, tolerability, and efficacy of inclisiran in ad... | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) GR (Ongoing) NL (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002276-25 | Sponsor Protocol Number: 20120124 | Start Date*: 2016-10-21 | ||||||||||||||||
Sponsor Name:Amgen Inc | ||||||||||||||||||
Full Title: Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects Fr... | ||||||||||||||||||
Medical condition: Hypercholesterolemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) HU (Completed) AT (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) NL (Completed) PT (Completed) SI (Completed) PL (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002000-31 | Sponsor Protocol Number: FSJD-ISON-2016 | Start Date*: 2016-09-21 |
Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU | ||
Full Title: Open clinical trial phase IIa to study the isoniazid suspension absoption of 10mg/ml for the tuberculosis infection treatment in patients under the age of 6 | ||
Medical condition: tuberculosis infection in patients under the age of 6 | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003376-49 | Sponsor Protocol Number: MDCO-PCS-16-02 | Start Date*: 2017-06-20 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017091-25 | Sponsor Protocol Number: P081110 | Start Date*: 2010-07-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-... | |||||||||||||
Medical condition: Drépanocytose homozygote présentant une microalbuminurie associée à une hyperfiltration glomérulaire | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003449-15 | Sponsor Protocol Number: 301012-CS5 | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:Genzyme Europe B.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects | |||||||||||||
Medical condition: Reduction of low density lipoprotein C (LDL-C) in Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002687-41 | Sponsor Protocol Number: TA-8995-AD-1 | Start Date*: 2021-12-09 |
Sponsor Name:NewAmsterdam Pharma BV | ||
Full Title: A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carr... | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005400-15 | Sponsor Protocol Number: 20110271 | Start Date*: 2012-03-22 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia | |||||||||||||
Medical condition: Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GR (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005399-40 | Sponsor Protocol Number: 20110233 | Start Date*: 2012-03-09 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A two part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) ES (Completed) IT (Completed) NL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003806-33 | Sponsor Protocol Number: AEGR-733-020 | Start Date*: 2016-06-30 | |||||||||||
Sponsor Name:Aegerion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable ... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolemia (HoFH). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000351-95 | Sponsor Protocol Number: R727-CL-1628 | Start Date*: 2017-07-18 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||
Medical condition: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002278-30 | Sponsor Protocol Number: APH-19 | Start Date*: 2020-08-12 | |||||||||||
Sponsor Name:Amryt Pharmaceuticals DAC | |||||||||||||
Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001638-33 | Sponsor Protocol Number: IKEM-CEM-01 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Institute for Clinical and Experimental Medicine | |||||||||||||
Full Title: Cholesterol 7alpha-hydroxylase polymorphism as a predictor cholesterolemia responsiveness | |||||||||||||
Medical condition: hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004394-49 | Sponsor Protocol Number: LIB003-007 | Start Date*: 2021-08-12 | |||||||||||||||||||||
Sponsor Name:LIB Therapeutics, LLC | |||||||||||||||||||||||
Full Title: Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at ... | |||||||||||||||||||||||
Medical condition: Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004949-28 | Sponsor Protocol Number: P071003 | Start Date*: 2009-09-04 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Traitement par le monoxyde d’azote inhalé (NO) du syndrome thoracique aigu (STA) chez l'enfant drépanocytaire : Essai randomisé, double aveugle, contre placebo, preuve de concept | |||||||||||||
Medical condition: Traitement du syndrome thoracique aigu (STA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017940-15 | Sponsor Protocol Number: P081227 | Start Date*: 2010-04-20 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Devenir de la spermatogénèse chez les hommes drépanocytaires traités médicalement (HYDREP). | |||||||||||||
Medical condition: Drépanocytose | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.